STXS · XBRL financial data

Stereotaxis financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (STXS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	26,630	35,021	28,147	26,771	26,918	32,377
Cost of revenue	7,664	11,789	9,677	11,911	12,324	15,306
Gross profit	18,966	23,232	18,470	14,860	14,594	17,071
Research and development	8,137	10,199	10,558	10,273	9,760	9,383
General and administrative	6,364	13,973	14,363	14,050	17,201	17,849
Total operating expenses	25,680	36,120	37,246	36,699	39,333	39,183
Operating income (loss)	(6,714)	(12,888)	(18,776)	(21,839)	(24,739)	(22,112)
Interest income	—	100	—	—	—	—
Other income (expense)	—	—	—	30	—	2
Net income (loss)	(6,646)	(10,716)	(18,292)	(20,713)	(24,045)	(21,643)
Earnings per share, basic USD per share	(0.11)	(0.16)	(0.26)	(0.27)	(0.30)	(0.25)
Earnings per share, diluted USD per share	(0.11)	(0.16)	(0.26)	(0.27)	(0.30)	(0.25)
Weighted average shares, basic thousands of shares	72,746	75,558	76,061	80,702	85,183	90,957
Weighted average shares, diluted thousands of shares	72,746	75,558	76,061	80,702	85,183	90,957

Fiscal years (STXS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	43,940	38,739	8,586	19,818	12,217	13,421
Short-term investments	—	—	19,844	—	0	0
Accounts receivable	3,515	5,406	5,090	3,822	3,824	5,847
Inventory	3,295	4,433	7,876	8,426	8,331	9,567
Prepaid and other current assets	1,716	2,356	1,325	676	1,848	698
Total current assets	52,717	51,388	43,246	33,267	26,439	33,849
Property and equipment, net	195	2,632	3,831	3,304	3,573	3,019
Right-of-use asset	2,235	5,735	5,384	4,982	5,483	4,912
Goodwill	—	—	—	—	3,764	3,764
Total assets	55,456	60,985	53,413	41,909	46,724	52,251
Accounts payable	1,609	4,188	3,270	3,190	5,668	4,768
Accrued liabilities	3,209	2,528	3,306	2,972	2,922	2,065
Total current liabilities	13,573	13,262	14,291	13,247	21,602	22,360
Long-term debt	973	—	—	—	—	—
Lease liability, non-current	—	5,842	5,488	5,062	5,436	4,794
Total liabilities	15,227	21,561	21,484	19,989	35,292	33,530
Accumulated deficit	(487,959)	(498,675)	(516,967)	(537,680)	(561,725)	(583,368)
Total stockholders' equity	34,624	33,840	26,346	16,343	6,080	13,481
Total liabilities and equity	55,456	60,985	53,413	41,909	46,724	52,251
Common shares outstanding (cover page) thousands of shares	73,759	74,638	75,045	82,129	85,980	97,249

Fiscal years (STXS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(6,646)	(10,716)	(18,292)	(20,713)	(24,045)	(21,643)
Stock-based compensation	3,169	9,363	10,576	10,623	10,262	9,852
Net cash from operating activities	(3,512)	(2,946)	(8,415)	(9,139)	(8,497)	(13,685)
Net cash from investing activities	(71)	(1,397)	(22,094)	19,765	74	(93)
Proceeds from issuing common stock	15,182	547	220	81	297	15,656
Proceeds from issuing equity	—	—	—	—	—	3,100
Dividends paid	0	0	0	0	0	0
Net cash from financing activities	17,340	547	220	81	297	14,763
Net change in cash	13,757	(3,795)	(30,289)	10,707	(8,126)	985

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Stereotaxis	10,491	7,670	(3,675)*	100.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Profound Medical	38,271	2,483	(11,338)*	36.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Sanara MedTech	15,421	28,137	2,038*	9.2M	—	Q2 FY26 10-QJun 30, 2026
Anika Therapeutics	38,412	32,610	(684)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026
Sight Sciences	77,402	24,923	(2,402)*	55.6M	15.2 quarters	Q3 FY26 10-QSep 30, 2026
Semler Scientific	10,176	7,491	(32,950)*	15.2M	0.3 quarters	Q3 FY25 10-QSep 30, 2025
SkinHealth Systems	206,074	72,113	2,671*	130.1M	—	Q2 FY26 10-QJun 30, 2026
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Utah Medical Products	87,528	8,529	1,383*	3.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.